GB2481018A — Buprenorphine sustained release system
Assigned to Reckitt Benckiser Healthcare UK Ltd · Expires 2011-12-14 · 14y expired
What this patent protects
A flowable composition comprises: (a) at least one biodegradable thermoplastic polymer, which is at least substantially insoluble in body fluid; (b) a biocompatible polar aprotic organic liquid, which comprises an amide, an ester, a carbonate, a ketone, a lactam, an ether, a sulf…
USPTO Abstract
A flowable composition comprises: (a) at least one biodegradable thermoplastic polymer, which is at least substantially insoluble in body fluid; (b) a biocompatible polar aprotic organic liquid, which comprises an amide, an ester, a carbonate, a ketone, a lactam, an ether, a sulfonyl, or any combination thereof, which has a solubility in aqueous medium or body fluid ranging from insoluble to completely soluble; and (c) buprenorphine, a metabolite, or prodrug thereof. Preferably, the polymer is a polylactide, polyglycolide, polycaprolactone, polyorthoester, a copolymer or terpolymer thereof. The solvent may be N-methyl-2-pyrrolidone, 2-pyrrolidone, N,N-dimethylformamide, dimethylsulfoxide, propylene carbonate, caprolactam, triacetin PEG, or any combination thereof. A biodegradable implant may be formed by injecting the flowable composition into the body of a patient and allowing the polar aprotic liquid to dissipate to produce a solid biodegradable implant.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.